Live | Norway | Sweden | Denmark | Europe | USA | Currency | Goods | Grey market | NDXDelayed quotes. Last updated: Friday 20. October 17:37
Oslo Børs  | Oslo Axess  | Merkur  | Options  | ETNs  | Warrants  | OTC  | Bonds  | Bull & Bear
BerGenBio
Technical analysis
News
About BGBIO
Broker share
Intraday chart
Correlations
Trade log
Order Depth log
Data export
Add to interest list
Trade BGBIO
Real-time snapshot
Quotes for BGBIO (BerGenBio) at Oslo Børs
RT StockLastChangeChng%BuyerSellerOpenHighLowLastVolumeValueTrades
Delayed BGBIO 21.20-0.60 -2.75% 20.90 21.00 21.8022.2020.7021.8056 5171 205 30873
Delayed BGBIOO -0.00 0.00%     -------
Accumulated order book for BGBIO on Oslo Børs
Order Buyer depth Bid Offer Seller depth Order
1 2 500   20.70 21.00   10 1
4 2 350   20.60 21.10   657 1
2 525   20.10 21.20   9 718 2
2 1 150   20.00 21.40   400 1
1 1 000   19.80 21.90   180 1
2258 858Total buyers Total sellers 82 91249
Show all depths Bid/ask ratio: 0.71
Siste handler
Time Price Volume Buyer Seller
16:02:23 21.20 10 PAS NON
16:02:21 21.00 990 PAS DNM
16:02:08 21.00 1 000 DNM DNM
16:00:34 21.20 10 DNM DNM
15:54:21 20.90 52 DNM PAS
15:50:26 21.10 10 DNM MLI
15:47:02 20.70 52 PAS NON
15:47:02 20.70 298 PAS NON
15:47:02 20.70 4 702 PAS NON
15:47:02 20.70 667 MLI NON
15:47:02 20.80 315 NON NON
Bid-ask ratio
36%64%
Ordrebokstatus
After hours
History
Change last month 9.84%
Change last year 0.00%
Change last 3 months -15.20%
Change since New year's day -15.20%
Highest this year 25.00
Lowest this year 18.70
Highest since 07/04-2017 25.00
Lowest since 07/04-2017 18.70
Change from top -15.20%
Graphs for BGBIO
Intraday Chart for
Volume Intraday
Volume per price level
Secor index
Historical graph
Last five days
News last week
19/10-2017 08:00:21 BerGenBio Announces Start of PhII Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA for Patients with Advanced Breast Cancer (OBI)
  08:00:21 BerGenBio Announces Start of PhII Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA for Patients with Advanced Breast Cancer (OBI)
  08:00:00 BerGenBio Announces Start of PhII Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA for Patients with Advanced Breast Cancer (Cision)
18/10-2017 08:31:00 God rekruttering av pasienter (Hegnar)
  08:00:27 BerGenBio announces strong recruitment and encouraging safety profile for AXL Inhibitor BGB324 in a melanoma study at 9th World Congress of Melanoma (OBI)
  08:00:26 BerGenBio announces strong recruitment and encouraging safety profile for AXL Inhibitor BGB324 in a melanoma study at 9th World Congress of Melanoma (OBI)
  08:00:00 BerGenBio announces strong recruitment and encouraging safety profile for AXL Inhibitor BGB324 in a melanoma study at 9th World Congress of Melanoma (Cision)
  08:00:00 BerGenBio announces strong recruitment and encouraging safety profile for AXL Inhibitor BGB324 in a melanoma study at 9th World Congress of Melanoma (Cision)
16/10-2017 08:00:12 BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured in 3 Clinical Presentations at 18th World Conference on Lung Cancer in Yokohama (OBI)
  08:00:11 Tre kliniske studier med BGB324, BerGenBio's Selektive First-in-Class AXL Hemmer, presenteres på den 18ende verdenskonferansen om lungekreft i Yokohma (OBI)
  08:00:00 Tre kliniske studier med BGB324, BerGenBio's Selektive First-in-Class AXL Hemmer, presenteres på den 18ende verdenskonferansen om lungekreft i Yokohma (Cision)
  08:00:00 BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured in 3 Clinical Presentations at 18th World Conference on Lung Cancer in Yokohama (Cision)
Quotes and trades continuously 15 minutes delayed.
Layout |  Help |  Print  | Change to real-time No markets open
Saturday 21/10-2017 01:33:44